{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T15:55:25Z","timestamp":1791474925548,"version":"4.3.4"},"reference-count":101,"publisher":"Georg Thieme Verlag KG","issue":"02","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Semin Thromb Hemost"],"published-print":{"date-parts":[[2026,3]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Venous thromboembolism (VTE) remains a major cause of preventable morbidity and mortality. Prophylaxis with anticoagulation is limited by bleeding risk, contraindications, and patient-specific factors. Interest has therefore grown in alternative or adjunctive nonanticoagulant strategies that can mitigate thrombotic risk without increasing bleeding complications. Aspirin has demonstrated efficacy in both primary and secondary prevention of VTE. Most studies and trials have been undertaken in an orthopaedic population but with favorable safety profile. Statins have been shown to reduce VTE incidence without increased bleeding in several trials. Metformin appears to reduce prothrombotic mechanisms in type 2 diabetes. Observational studies have suggested its use to lower VTE risk. However, randomized data are lacking. Glucagon-like peptide 1 receptor agonists (GLP-1 RAs) have been shown to reduce weight, improve metabolic control, and possess anti-inflammatory effects. Evidence suggests GLP-1 RAs may reduce VTE risk. However, findings are inconsistent across observational and trial-based analyses. Other emerging alternatives include hydroxychloroquine, proprotein convertase subtilisin\/kexin type 9 (PCSK9) inhibitors (post hoc analyses of cardiovascular trials suggesting lower VTE rates potentially via lipoprotein (a) reduction), sodium-glucose cotransporter-2 inhibitors (overall neutral in meta-analyses of randomized control trials with some real-world evidence vs. comparators), and renin\u2013angiotensin\u2013aldosterone system modulators (mixed observational data and no trial-proven benefit). Uncertainties remain regarding optimal patient selection, duration of prophylaxis, and their role in combination with standard anticoagulation across these drug classes. Further studies\/trials are warranted to define the efficacy, safety, and guideline positioning of these agents in diverse patient populations.<\/jats:p>","DOI":"10.1055\/a-2712-3534","type":"journal-article","created":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T23:09:46Z","timestamp":1760569786000},"page":"236-247","source":"Crossref","is-referenced-by-count":2,"title":["Nonanticoagulant Strategies for Venous Thromboembolism Prophylaxis"],"prefix":"10.1055","volume":"52","author":[{"given":"Gerard","family":"Gurumurthy","sequence":"additional","affiliation":[{"name":"The Queen Elizabeth Hospital King's Lynn NHS Foundation Trust, King's Lynn, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jecko","family":"Thachil","sequence":"additional","affiliation":[{"name":"Department of Haematology, Manchester University NHS Foundation Trust, Manchester, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"194","published-online":{"date-parts":[[2025,10,15]]},"reference":[{"issue":"04","key":"ref1","doi-asserted-by":"crossref","first-page":"100325","DOI":"10.1016\/j.clinme.2025.100325","article-title":"Is pulmonary embolism a chronic disease?","volume":"25","author":"G Gurumurthy","year":"2025","journal-title":"Clin Med (Lond)"},{"issue":"08","key":"ref2","doi-asserted-by":"crossref","first-page":"2467","DOI":"10.3390\/jcm9082467","article-title":"Prevention of venous thromboembolism in 2020 and beyond","volume":"9","author":"M Nicholson","year":"2020","journal-title":"J Clin Med"},{"issue":"04","key":"ref3","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1177\/14782715221134720","article-title":"Challenges in managing patients on anticoagulation: thrombocytopenia, resumption after bleeding and recurrent thrombosis","volume":"52","author":"D Swan","year":"2022","journal-title":"J R Coll Physicians Edinb"},{"issue":"08","key":"ref4","doi-asserted-by":"crossref","first-page":"1910","DOI":"10.1111\/jth.15776","article-title":"Management of bleeding risk in patients who receive anticoagulant therapy for venous thromboembolism: Communication from the ISTH SSC Subcommittee on Predictive and Diagnostic Variables in Thrombotic Disease","volume":"20","author":"P L den Exter","year":"2022","journal-title":"J Thromb Haemost"},{"issue":"03","key":"ref6","doi-asserted-by":"crossref","first-page":"e319","DOI":"10.1055\/s-0041-1729171","article-title":"Prediction of major bleeding in anticoagulated patients for venous thromboembolism: comparison of the RIETE and the VTE-BLEED scores","volume":"5","author":"R Lecumberri","year":"2021","journal-title":"TH Open"},{"issue":"02","key":"ref7","doi-asserted-by":"crossref","first-page":"362","DOI":"10.3390\/jcm13020362","article-title":"A comprehensive review of risk factors and thrombophilia evaluation in venous thromboembolism","volume":"13","author":"A B Dicks","year":"2024","journal-title":"J Clin Med"},{"issue":"08","key":"ref8","doi-asserted-by":"crossref","first-page":"2015","DOI":"10.1007\/s40620-022-01413-x","article-title":"A systematic review of the efficacy and safety of anticoagulants in advanced chronic kidney disease","volume":"35","author":"K Parker","year":"2022","journal-title":"J Nephrol"},{"issue":"02","key":"ref9","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1111\/bjh.14599","article-title":"Reintroduction of anti-thrombotic therapy after a gastrointestinal haemorrhage: if and when?","volume":"177","author":"M J Scott","year":"2017","journal-title":"Br J Haematol"},{"issue":"03","key":"ref10","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1007\/s00281-022-00916-w","article-title":"Mechanisms of immunothrombosis and vasculopathy in antiphospholipid syndrome","volume":"44","author":"J S Knight","year":"2022","journal-title":"Semin Immunopathol"},{"issue":"151","key":"ref11","doi-asserted-by":"crossref","first-page":"180119","DOI":"10.1183\/16000617.0119-2018","article-title":"Cancer-associated thrombosis: the when, how and why","volume":"28","author":"C J Fernandes","year":"2019","journal-title":"Eur Respir Rev"},{"issue":"07","key":"ref12","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1055\/s-0035-1564040","article-title":"Cancer tissue procoagulant mechanisms and the hypercoagulable state of patients with cancer","volume":"41","author":"A Falanga","year":"2015","journal-title":"Semin Thromb Hemost"},{"issue":"05","key":"ref13","doi-asserted-by":"crossref","first-page":"102985","DOI":"10.1016\/j.rpth.2025.102985","article-title":"Radiotherapy-the not-so-insignificant contributor to cancer-associated venous thrombosis","volume":"9","author":"G Gurumurthy","year":"2025","journal-title":"Res Pract Thromb Haemost"},{"issue":"01","key":"ref14","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.beha.2008.12.009","article-title":"Procoagulant mechanisms in tumour cells","volume":"22","author":"A Falanga","year":"2009","journal-title":"Best Pract Res Clin Haematol"},{"issue":"06","key":"ref15","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1111\/jth.12955","article-title":"Recurrent venous thromboembolism in anticoagulated patients with cancer: management and short-term prognosis","volume":"13","author":"S Schulman","year":"2015","journal-title":"J Thromb Haemost"},{"issue":"02","key":"ref16","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1007\/s11912-019-0767-5","article-title":"Anticoagulation in cancer patients: a summary of pitfalls to avoid","volume":"21","author":"H K Patel","year":"2019","journal-title":"Curr Oncol Rep"},{"issue":"06","key":"ref17","doi-asserted-by":"crossref","first-page":"102162","DOI":"10.1016\/j.rpth.2023.102162","article-title":"Thromboembolism in nephrotic syndrome: controversies and uncertainties","volume":"7","author":"K Parker","year":"2023","journal-title":"Res Pract Thromb Haemost"},{"issue":"05","key":"ref18","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1093\/ckj\/sfu080","article-title":"Anticoagulation in chronic kidney disease patients-the practical aspects","volume":"7","author":"S Hughes","year":"2014","journal-title":"Clin Kidney J"},{"issue":"21","key":"ref19","doi-asserted-by":"crossref","first-page":"12772","DOI":"10.3390\/ijms232112772","article-title":"Platelets and Their Role in Hemostasis and Thrombosis-From Physiology to Pathophysiology and Therapeutic Implications","volume":"23","author":"A Scridon","year":"2022","journal-title":"Int J Mol Sci"},{"issue":"04","key":"ref20","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1111\/j.1365-2125.2011.03943.x","article-title":"Anti-platelet therapy: cyclo-oxygenase inhibition and the use of aspirin with particular regard to dual anti-platelet therapy","volume":"72","author":"T D Warner","year":"2011","journal-title":"Br J Clin Pharmacol"},{"issue":"08","key":"ref21","first-page":"e0235628","article-title":"Aspirin versus low-molecular-weight heparin for venous thromboembolism prophylaxis in orthopaedic trauma patients: A patient-centered randomized controlled trial","volume":"15","author":"B E Haac","year":"2020"},{"issue":"03","key":"ref22","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1056\/NEJMoa2205973","article-title":"Aspirin or low-molecular-weight heparin for thromboprophylaxis after a fracture","volume":"388","author":"R V O'Toole","year":"2023","journal-title":"N Engl J Med"},{"issue":"01","key":"ref23","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1186\/s13018-024-05356-w","article-title":"Low-versus high-dose aspirin for venous thromboembolic prophylaxis after total joint arthroplasty: a systematic review and meta-analysis","volume":"19","author":"P Mirghaderi","year":"2024","journal-title":"J Orthop Surg Res"},{"issue":"03","key":"ref24","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1001\/jamainternmed.2019.6108","article-title":"Clinical effectiveness and safety of aspirin for venous thromboembolism prophylaxis after total hip and knee replacement: a systematic review and meta-analysis of randomized clinical trials","volume":"180","author":"G S Matharu","year":"2020","journal-title":"JAMA Intern Med"},{"issue":"07","key":"ref25","doi-asserted-by":"crossref","first-page":"760","DOI":"10.2106\/JBJS.24.00946","article-title":"Aspirin is as effective and safe as oral anticoagulants for venous thromboembolism prophylaxis after joint arthroplasty: a systematic review and meta-analysis of randomized clinical trials","volume":"107","author":"Z Hong","year":"2025","journal-title":"J Bone Joint Surg Am"},{"issue":"01","key":"ref26","doi-asserted-by":"crossref","first-page":"17213","DOI":"10.1038\/s41598-025-02171-z","article-title":"Aspirin for the extended prevention of venous thromboembolism: a meta-analysis and trial sequential analysis","volume":"15","author":"M Carron","year":"2025","journal-title":"Sci Rep"},{"issue":"13","key":"ref27","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1161\/CIRCULATIONAHA.114.008828","article-title":"Aspirin for the prevention of recurrent venous thromboembolism: the INSPIRE collaboration","volume":"130","author":"J Simes","year":"2014","journal-title":"Circulation"},{"issue":"13","key":"ref28","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1056\/NEJMoa1700518","article-title":"Rivaroxaban or aspirin for extended treatment of venous thromboembolism","volume":"376","author":"J I Weitz","year":"2017","journal-title":"N Engl J Med"},{"issue":"08","key":"ref29","doi-asserted-by":"crossref","first-page":"e933","DOI":"10.1097\/HS9.0000000000000933","article-title":"Aspirin as thromboprophylaxis in orthopedic surgery: a matter of perspective","volume":"7","author":"R EG Schutgens","year":"2023","journal-title":"HemaSphere"},{"issue":"06","key":"ref30","doi-asserted-by":"crossref","first-page":"381S","DOI":"10.1378\/chest.08-0656","article-title":"Prevention of venous thromboembolism: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition)","volume":"133","author":"W H Geerts","year":"2008","journal-title":"Chest"},{"issue":"22","key":"ref31","doi-asserted-by":"crossref","first-page":"3198","DOI":"10.1182\/bloodadvances.2018022954","article-title":"American Society of Hematology 2018 guidelines for management of venous thromboembolism: prophylaxis for hospitalized and nonhospitalized medical patients","volume":"2","author":"H J Sch\u00fcnemann","year":"2018","journal-title":"Blood Adv"},{"issue":"01","key":"ref32","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1182\/hematology.2020000150","article-title":"Does aspirin prevent venous thromboembolism?","volume":"2020","author":"R Diep","year":"2020","journal-title":"Hematology (Am Soc Hematol Educ Program)"},{"issue":"01","key":"ref33","doi-asserted-by":"crossref","first-page":"b2376","DOI":"10.1136\/bmj.b2376","article-title":"The benefits of statins in people without established cardiovascular disease but with cardiovascular risk factors: meta-analysis of randomised controlled trials","volume":"338","author":"J J Brugts","year":"2009","journal-title":"BMJ"},{"issue":"S 03","key":"ref34","doi-asserted-by":"crossref","first-page":"S207","DOI":"10.21037\/cdt.2017.09.12","article-title":"Statins as a preventative therapy for venous thromboembolism","volume":"7","author":"A Wallace","year":"2017","journal-title":"Cardiovasc Diagn Ther"},{"issue":"08","key":"ref35","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1089\/ars.2013.5430","article-title":"Statins as regulators of redox state in the vascular endothelium: beyond lipid lowering","volume":"20","author":"M Margaritis","year":"2014","journal-title":"Antioxid Redox Signal"},{"issue":"07","key":"ref36","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1016\/j.molimm.2005.06.045","article-title":"Statins and nitric oxide reduce C-reactive protein production while inflammatory conditions persist","volume":"43","author":"B Voleti","year":"2006","journal-title":"Mol Immunol"},{"issue":"23","key":"ref37","doi-asserted-by":"crossref","first-page":"2719","DOI":"10.3390\/cells12232719","article-title":"Statins effects on blood clotting: a review","volume":"12","author":"C Siniscalchi","year":"2023","journal-title":"Cells"},{"issue":"01","key":"ref38","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/S0002-9149(00)00831-6","article-title":"Effects of simvastatin or hormone replacement therapy, or both, on fibrinogen, factor VII, and plasminogen activator inhibitor levels in postmenopausal women with proven coronary artery disease","volume":"86","author":"E Sbarouni","year":"2000","journal-title":"Am J Cardiol"},{"issue":"02","key":"ref39","doi-asserted-by":"crossref","first-page":"e83","DOI":"10.1016\/S2352-3026(16)30184-3","article-title":"Statins and primary prevention of venous thromboembolism: a systematic review and meta-analysis","volume":"4","author":"S K Kunutsor","year":"2017","journal-title":"Lancet Haematol"},{"issue":"18","key":"ref40","doi-asserted-by":"crossref","first-page":"1851","DOI":"10.1056\/NEJMoa0900241","article-title":"A randomized trial of rosuvastatin in the prevention of venous thromboembolism","volume":"360","author":"R J Glynn","year":"2009","journal-title":"N Engl J Med"},{"issue":"11","key":"ref41","doi-asserted-by":"crossref","first-page":"e003135","DOI":"10.1136\/bmjopen-2013-003135","article-title":"Statin treatment and risk of recurrent venous thromboembolism: a nationwide cohort study","volume":"3","author":"C D Nguyen","year":"2013","journal-title":"BMJ Open"},{"issue":"01","key":"ref42","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1111\/jth.15537","article-title":"Statins for venous event reduction in patients with venous thromboembolism: a multicenter randomized controlled pilot trial assessing feasibility","volume":"20","author":"A Delluc","year":"2022","journal-title":"J Thromb Haemost"},{"issue":"06","key":"ref43","first-page":"631","article-title":"Statin therapy: review of safety and potential side effects","volume":"32","author":"S Ramkumar","year":"2016","journal-title":"Acta Cardiol Sin"},{"issue":"05","key":"ref44","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1016\/j.thromres.2014.09.001","article-title":"Statins are associated with low risk of venous thromboembolism in patients with cancer: a prospective and observational cohort study","volume":"134","author":"F L\u00f6tsch","year":"2014","journal-title":"Thromb Res"},{"issue":"02","key":"ref45","first-page":"e0116621","article-title":"Statins Improve the Resolution of Established Murine Venous Thrombosis: Reductions in Thrombus Burden and Vein Wall Scarring","volume":"10","author":"C W Kessinger","year":"2015"},{"issue":"18","key":"ref46","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1056\/NEJMoa1615664","article-title":"Evolocumab and clinical outcomes in patients with cardiovascular disease","volume":"376","author":"M S Sabatine","year":"2017","journal-title":"N Engl J Med"},{"issue":"09","key":"ref47","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.3390\/ph16091197","article-title":"The anti-thrombotic effects of PCSK9 inhibitors","volume":"16","author":"M J P\u00e9\u010d","year":"2023","journal-title":"Pharmaceuticals (Basel)"},{"issue":"12","key":"ref48","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1161\/CIRCULATIONAHA.118.037184","article-title":"Lipoprotein(a), PCSK9 inhibition, and cardiovascular risk","volume":"139","author":"M L O'Donoghue","year":"2019","journal-title":"Circulation"},{"issue":"05","key":"ref49","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1194\/jlr.R060582","article-title":"Lipoprotein (a): truly a direct prothrombotic factor in cardiovascular disease?","volume":"57","author":"M B Boffa","year":"2016","journal-title":"J Lipid Res"},{"key":"ref50","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.atherosclerosis.2022.04.009","article-title":"Beyond fibrinolysis: the confounding role of Lp(a) in thrombosis","volume":"349","author":"M B Boffa","year":"2022","journal-title":"Atherosclerosis"},{"issue":"22","key":"ref51","doi-asserted-by":"crossref","first-page":"2097","DOI":"10.1056\/NEJMoa1801174","article-title":"Alirocumab and cardiovascular outcomes after acute coronary syndrome","volume":"379","author":"G G Schwartz","year":"2018","journal-title":"N Engl J Med"},{"issue":"20","key":"ref52","doi-asserted-by":"crossref","first-page":"1600","DOI":"10.1161\/CIRCULATIONAHA.120.046397","article-title":"The effect of PCSK9 (Proprotein Convertase Subtilisin\/Kexin Type 9) inhibition on the risk of venous thromboembolism","volume":"141","author":"N A Marston","year":"2020","journal-title":"Circulation"},{"issue":"07","key":"ref53","doi-asserted-by":"crossref","first-page":"1732","DOI":"10.1161\/ATVBAHA.112.248765","article-title":"Genetic evidence that lipoprotein(a) associates with atherosclerotic stenosis rather than venous thrombosis","volume":"32","author":"P R Kamstrup","year":"2012","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"39","key":"ref54","doi-asserted-by":"crossref","first-page":"3925","DOI":"10.1093\/eurheartj\/ehac361","article-title":"Lipoprotein(a) in atherosclerotic cardiovascular disease and aortic stenosis: a European Atherosclerosis Society consensus statement","volume":"43","author":"F Kronenberg","year":"2022","journal-title":"Eur Heart J"},{"issue":"12","key":"ref55","doi-asserted-by":"crossref","first-page":"2082","DOI":"10.1194\/jlr.P094763","article-title":"Potent reduction of plasma lipoprotein (a) with an antisense oligonucleotide in human subjects does not affect ex vivo fibrinolysis","volume":"60","author":"M B Boffa","year":"2019","journal-title":"J Lipid Res"},{"issue":"05","key":"ref56","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1007\/s00125-005-1715-5","article-title":"The risk of venous thromboembolism is markedly elevated in patients with diabetes","volume":"48","author":"V Petrauskiene","year":"2005","journal-title":"Diabetologia"},{"issue":"08","key":"ref57","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.1111\/j.1538-7836.2010.03910.x","article-title":"Hyperglycemia: a prothrombotic factor?","volume":"8","author":"B A Lemkes","year":"2010","journal-title":"J Thromb Haemost"},{"issue":"S 01","key":"ref58","doi-asserted-by":"crossref","first-page":"31","DOI":"10.2165\/00003495-199958001-00009","article-title":"The antihyperglycaemic effect of metformin: therapeutic and cellular mechanisms","volume":"58","author":"N F Wiernsperger","year":"1999","journal-title":"Drugs"},{"issue":"04","key":"ref59","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1007\/s00592-011-0276-y","article-title":"The effects of rosiglitazone and metformin on inflammation and endothelial dysfunction in patients with type 2 diabetes mellitus","volume":"48","author":"E Fidan","year":"2011","journal-title":"Acta Diabetol"},{"issue":"10","key":"ref60","doi-asserted-by":"crossref","first-page":"10773","DOI":"10.18632\/oncotarget.7387","article-title":"Metformin regulates oxLDL-facilitated endothelial dysfunction by modulation of SIRT1 through repressing LOX-1-modulated oxidative signaling","volume":"7","author":"C H Hung","year":"2016","journal-title":"Oncotarget"},{"issue":"01","key":"ref61","doi-asserted-by":"crossref","first-page":"36222","DOI":"10.1038\/srep36222","article-title":"Metformin uniquely prevents thrombosis by inhibiting platelet activation and mtDNA release","volume":"6","author":"G Xin","year":"2016","journal-title":"Sci Rep"},{"issue":"05","key":"ref62","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1093\/aje\/kwab291","article-title":"Association of metformin use with risk of venous thromboembolism in adults with type 2 diabetes: a general-population-based cohort study","volume":"191","author":"T Sha","year":"2022","journal-title":"Am J Epidemiol"},{"issue":"06","key":"ref63","doi-asserted-by":"crossref","first-page":"161","DOI":"10.14740\/jem848","article-title":"Protective effect of metformin on venous thrombosis in diabetic patients: findings from a systematic review","volume":"12","author":"S Alqahtani","year":"2022","journal-title":"J Endocrinol Metab"},{"issue":"06","key":"ref64","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1056\/NEJMoa2107519","article-title":"Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes","volume":"385","author":"J P Fr\u00edas","year":"2021","journal-title":"N Engl J Med"},{"issue":"06","key":"ref65","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1111\/j.1538-7836.2012.04707.x","article-title":"Insulin resistance and risk of venous thromboembolism: results of a population-based cohort study","volume":"10","author":"I M Van Schouwenburg","year":"2012","journal-title":"J Thromb Haemost"},{"issue":"07","key":"ref67","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1016\/j.jacbts.2022.04.004","article-title":"Glucagon-like peptide-1 receptor regulates thromboxane-induced human platelet activation","volume":"7","author":"K N Cahill","year":"2022","journal-title":"JACC Basic Transl Sci"},{"issue":"10","key":"ref68","doi-asserted-by":"crossref","first-page":"2410","DOI":"10.1182\/bloodadvances.2025015871","article-title":"Glucagon-like peptide 1 receptor agonists and venous thromboembolism in type 2 diabetes: a target trial emulation","volume":"9","author":"C H Chiang","year":"2025","journal-title":"Blood Adv"},{"issue":"07","key":"ref69","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1055\/a-2546-0353","article-title":"Novel antidiabetic drugs and risk of venous thromboembolism: a literature review","volume":"51","author":"Q Chen","year":"2025","journal-title":"Semin Thromb Hemost"},{"key":"ref70","doi-asserted-by":"crossref","first-page":"1788","DOI":"10.1016\/S0140-6736(22)02074-8","article-title":"Impact of diabetes on the effects of sodium glucose co-transporter-2 inhibitors on kidney outcomes: collaborative meta-analysis of large placebo-controlled trials","volume":"400","author":"C Baigent","year":"2022","journal-title":"Lancet"},{"issue":"01","key":"ref71","doi-asserted-by":"crossref","first-page":"e3174","DOI":"10.1002\/dmrr.3174","article-title":"Effects of sodium-glucose cotransporter 2 inhibitors on risk of venous thromboembolism in patients with type 2 diabetes: a systematic review and meta-analysis","volume":"36","author":"A Wang","year":"2020","journal-title":"Diabetes Metab Res Rev"},{"issue":"07","key":"ref72","doi-asserted-by":"crossref","first-page":"1707","DOI":"10.1007\/s12325-017-0573-0","article-title":"Safety and tolerability of empagliflozin in patients with type 2 diabetes: pooled analysis of phase I-III clinical trials","volume":"34","author":"S Kohler","year":"2017","journal-title":"Adv Ther"},{"key":"ref73","first-page":"100335","article-title":"SGLT2 inhibitors: beyond glycemic control","volume":"35","author":"I Hasan","year":"2024","journal-title":"J Clin Transl Endocrinol"},{"key":"ref74","doi-asserted-by":"crossref","first-page":"1008922","DOI":"10.3389\/fcvm.2022.1008922","article-title":"Anti-inflammatory role of SGLT2 inhibitors as part of their anti-atherosclerotic activity: data from basic science and clinical trials","volume":"9","author":"L Scisciola","year":"2022","journal-title":"Front Cardiovasc Med"},{"issue":"03","key":"ref75","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1007\/s40265-019-1057-0","article-title":"Emerging role of SGLT-2 inhibitors for the treatment of obesity","volume":"79","author":"M J Pereira","year":"2019","journal-title":"Drugs"},{"issue":"11","key":"ref76","doi-asserted-by":"crossref","first-page":"107703","DOI":"10.1016\/j.jdiacomp.2020.107703","article-title":"Empagliflozin decreases the plasma concentration of plasminogen activator inhibitor-1 (PAI-1) in patients with type 2 diabetes: association with improvement of fibrinolysis","volume":"34","author":"S Sakurai","year":"2020","journal-title":"J Diabetes Complications"},{"issue":"02","key":"ref77","doi-asserted-by":"crossref","first-page":"e3739","DOI":"10.1002\/dmrr.3739","article-title":"Sodium-glucose co-transporter-2 inhibitors and the risk of venous thromboembolism: a nationwide population-based study and meta-analysis","volume":"40","author":"H R Tsai","year":"2024","journal-title":"Diabetes Metab Res Rev"},{"issue":"08","key":"ref78","doi-asserted-by":"crossref","first-page":"e12476","DOI":"10.15252\/emmm.202012476","article-title":"Hydroxychloroquine in rheumatic autoimmune disorders and beyond","volume":"12","author":"E L Nirk","year":"2020","journal-title":"EMBO Mol Med"},{"issue":"01","key":"ref79","doi-asserted-by":"crossref","first-page":"e000681","DOI":"10.1136\/lupus-2022-000681","article-title":"Influence of hydroxychloroquine blood levels on adhesion molecules associated with endothelial dysfunction in patients with systemic lupus erythematosus","volume":"9","author":"S Fasano","year":"2022","journal-title":"Lupus Sci Med"},{"issue":"01","key":"ref80","doi-asserted-by":"crossref","first-page":"e000475","DOI":"10.1136\/lupus-2021-000475","article-title":"Hydroxychloroquine is associated with lower platelet activity and improved vascular health in systemic lupus erythematosus","volume":"8","author":"M G Cornwell","year":"2021","journal-title":"Lupus Sci Med"},{"issue":"01","key":"ref81","doi-asserted-by":"crossref","first-page":"30","DOI":"10.3899\/jrheum.120157","article-title":"Hydroxychloroquine use is associated with lower odds of persistently positive antiphospholipid antibodies and\/or lupus anticoagulant in systemic lupus erythematosus","volume":"40","author":"A Broder","year":"2013","journal-title":"J Rheumatol"},{"issue":"03","key":"ref82","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1097\/RHU.0000000000000502","article-title":"Use of hydroxychloroquine is associated with improved lipid profile in rheumatoid arthritis patients","volume":"23","author":"J F Restrepo","year":"2017","journal-title":"J Clin Rheumatol"},{"issue":"01","key":"ref83","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1182\/asheducation-2016.1.714","article-title":"What is the role of hydroxychloroquine in reducing thrombotic risk in patients with antiphospholipid antibodies?","volume":"2016","author":"T F Wang","year":"2016","journal-title":"Hematology (Am Soc Hematol Educ Program)"},{"issue":"09","key":"ref84","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1177\/0961203306071872","article-title":"Effect of antimalarials on thrombosis and survival in patients with systemic lupus erythematosus","volume":"15","author":"G Ruiz-Irastorza","year":"2006","journal-title":"Lupus"},{"issue":"01","key":"ref85","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1002\/art.24232","article-title":"Risk factors for thrombosis and primary thrombosis prevention in patients with systemic lupus erythematosus with or without antiphospholipid antibodies","volume":"61","author":"M G Tektonidou","year":"2009","journal-title":"Arthritis Rheum"},{"issue":"02","key":"ref86","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1136\/ard.2008.093013","article-title":"Risk and protective factors for thrombosis in systemic lupus erythematosus: results from a large, multi-ethnic cohort","volume":"68","author":"R Kaiser","year":"2009","journal-title":"Ann Rheum Dis"},{"issue":"03","key":"ref87","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1002\/art.27289","article-title":"The protective effect of antimalarial drugs on thrombovascular events in systemic lupus erythematosus","volume":"62","author":"H Jung","year":"2010","journal-title":"Arthritis Rheum"},{"issue":"03","key":"ref88","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/j.autrev.2014.10.019","article-title":"Patient-level analysis of five international cohorts further confirms the efficacy of aspirin for the primary prevention of thrombosis in patients with antiphospholipid antibodies","volume":"14","author":"L Arnaud","year":"2015","journal-title":"Autoimmun Rev"},{"issue":"09","key":"ref89","doi-asserted-by":"crossref","first-page":"2774","DOI":"10.1002\/art.21224","article-title":"Incidence and risk factors of thromboembolism in systemic lupus erythematosus: a comparison of three ethnic groups","volume":"52","author":"C C Mok","year":"2005","journal-title":"Arthritis Rheum"},{"issue":"10","key":"ref90","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1093\/rheumatology\/kei014","article-title":"Systemic lupus erythematosus in a multiethnic cohort (LUMINA): XXVIII. Factors predictive of thrombotic events","volume":"44","author":"K T Ho","year":"2005","journal-title":"Rheumatology (Oxford)"},{"issue":"10","key":"ref91","doi-asserted-by":"crossref","first-page":"1927","DOI":"10.1111\/jth.12363","article-title":"Antithrombotic effects of hydroxychloroquine in primary antiphospholipid syndrome patients","volume":"11","author":"A Schmidt-Tanguy","year":"2013","journal-title":"J Thromb Haemost"},{"issue":"06","key":"ref92","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1016\/j.autrev.2014.01.053","article-title":"14th International Congress on Antiphospholipid Antibodies: task force report on antiphospholipid syndrome treatment trends","volume":"13","author":"D Erkan","year":"2014","journal-title":"Autoimmun Rev"},{"issue":"01","key":"ref93","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1136\/ard-2023-224762","article-title":"EULAR recommendations for the management of systemic lupus erythematosus: 2023 update","volume":"83","author":"A Fanouriakis","year":"2024","journal-title":"Ann Rheum Dis"},{"issue":"12","key":"ref94","doi-asserted-by":"crossref","first-page":"2212","DOI":"10.1093\/rheumatology\/kex357","article-title":"Effect of long-term hydroxychloroquine on vascular events in patients with systemic lupus erythematosus: a database prospective cohort study","volume":"56","author":"C Y Hsu","year":"2017","journal-title":"Rheumatology (Oxford)"},{"issue":"03","key":"ref95","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1172\/JCI117809","article-title":"Angiotensin II regulates the expression of plasminogen activator inhibitor-1 in cultured endothelial cells. A potential link between the renin-angiotensin system and thrombosis","volume":"95","author":"D E Vaughan","year":"1995","journal-title":"J Clin Invest"},{"issue":"01","key":"ref96","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1007\/s11357-011-9207-7","article-title":"Mechanism of Ang II involvement in activation of NF-\u03baB through phosphorylation of p65 during aging","volume":"34","author":"J M Kim","year":"2012","journal-title":"Age (Dordr)"},{"issue":"09","key":"ref97","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1515\/hsz-2012-0348","article-title":"ACE inhibition enhances bradykinin relaxations through nitric oxide and B1 receptor activation in bovine coronary arteries","volume":"394","author":"K M Gauthier","year":"2013","journal-title":"Biol Chem"},{"issue":"02","key":"ref98","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1007\/s40119-019-00150-w","article-title":"A review of the role of bradykinin and nitric oxide in the cardioprotective action of angiotensin-converting enzyme inhibitors: focus on perindopril","volume":"8","author":"A Ancion","year":"2019","journal-title":"Cardiol Ther"},{"issue":"01","key":"ref99","first-page":"e87813","article-title":"Inhibition of renin angiotensin axis may be associated with reduced risk of developing venous thromboembolism in patients with atherosclerotic disease","volume":"9","author":"Y K Chae","year":"2014"},{"issue":"17","key":"ref100","doi-asserted-by":"crossref","first-page":"e026143","DOI":"10.1161\/JAHA.122.026143","article-title":"Renin-angiotensin system inhibitors in patients with COVID-19: a meta-analysis of randomized controlled trials led by the International Society of Hypertension","volume":"11","author":"S R Gnanenthiran","year":"2022","journal-title":"J Am Heart Assoc"},{"issue":"21","key":"ref101","doi-asserted-by":"crossref","first-page":"5118","DOI":"10.1182\/blood.V116.21.5118.5118","article-title":"Are beta-receptor and angiotensin-blocking drugs protective against venous thromboembolism (VTE)? A population based case-control study","volume":"116","author":"A A Ashrani","year":"2010","journal-title":"Blood"},{"issue":"01","key":"ref102","doi-asserted-by":"crossref","first-page":"20230760","DOI":"10.1515\/med-2023-0760","article-title":"Aspirin versus LMWH for VTE prophylaxis after orthopedic surgery","volume":"18","author":"Q Wei","year":"2023","journal-title":"Open Med (Wars)"},{"issue":"03","key":"ref103","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1161\/ATVBAHA.109.184127","article-title":"Venous thromboembolism in pregnancy","volume":"29","author":"A H James","year":"2009","journal-title":"Arterioscler Thromb Vasc Biol"}],"container-title":["Seminars in Thrombosis and Hemostasis"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.1055\/a-2712-3534.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,10]],"date-time":"2026-02-10T23:33:22Z","timestamp":1770766402000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.thieme-connect.de\/DOI\/DOI?10.1055\/a-2712-3534"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,15]]},"references-count":101,"journal-issue":{"issue":"02","published-online":{"date-parts":[[2026,2,10]]},"published-print":{"date-parts":[[2026,3]]}},"URL":"https:\/\/doi.org\/10.1055\/a-2712-3534","archive":["Portico","CLOCKSS"],"relation":{},"ISSN":["0094-6176","1098-9064"],"issn-type":[{"value":"0094-6176","type":"print"},{"value":"1098-9064","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,15]]}}}